Noteworthy, the BCR of almost 30% of CLL patients displays nearly identical or highly homologous complementarity determining region 3 (CDR3), also known as “stereotyped” BCR, suggesting an antigen-driven path to CLL development. Here, BCR is linked to B-cell chronic lymphocytic leukemia.